SCHEMBL3170234

SCHEMBL3170234

CC(=O)NCCNc1cc(NC(=O)CN2C[C@@H](C)N(Cc3ccccc3)[C@@H](C)C2)nc(-c2ccccc2)n1

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ADORA1 P30542 8/20 0.42
▸ ADORA2A P29274 6/20 0.42
▸ ADORA3 P0DMS8 8/20 0.39
▸ ADORA2B P29275 4/20 0.39
▸ EGFR P00533 1/20 0.38
▸ HDAC1 Q13547 1/20 0.37
▸ HDAC6 Q9UBN7 1/20 0.37
▸ ALDH1A1 P00352 3/20 0.36
▸ CYP1A2 P05177 2/20 0.36
▸ CYP3A4 P08684 2/20 0.36
▸ CLK4 Q9HAZ1 2/20 0.36
▸ ALOX15 P16050 1/20 0.36
▸ MAPK1 P28482 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ CYP2D6 P10635 1/20 0.36
▸ TSHR P16473 1/20 0.36
▸ CYP2C19 P33261 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3170239 1.00 ADORA1 (0.42) ADORA1ADORA2AADORA3ADORA2BEGFR
SCHEMBL3163746 0.87 ALDH1A1 (0.50) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL3156207 0.84 ALDH1A1 (0.48) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL3177039 0.82 ALDH1A1 (0.45) ADORA1ADORA2AADORA3ADORA2BEGFR
SCHEMBL3162253 0.82 ALDH1A1 (0.52) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL3163330 0.82 NPSR1 (0.48) ALDH1A1
SCHEMBL3165629 0.82 GSK3B (0.40) ADORA1ADORA2AADORA3ADORA2BEGFR
SCHEMBL3163125 0.82 NPC1 (0.47) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL3164709 0.82 NPC1 (0.47) ADORA1ADORA2AADORA3ADORA2BALDH1A1
SCHEMBL3165191 0.81 ADORA2A (0.51) ADORA1ADORA2AADORA3ADORA2BALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1465631-B1 PYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE OSI PHARM INC (US) 2010-02-24 — — EP disclosed
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 — — US disclosed
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 — — US disclosed
US-7501407-B2 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2009-03-10 — — US disclosed
US-6916804-B2 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. (US) 2005-07-12 — — US disclosed
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2005-06-02 — — US disclosed
US-20030162764-A1 Pyrimidine A2b selective antagonist compounds, their synthesis and use OSI PHARMACEUTICALS, INC. 2003-08-28 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050119271-A1 Pyrimidine A2B selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 ADORA1 4/4885ADORA2A 2/4885ADORA3 3/4885
US-20030162764-A1 Pyrimidine A2b selective antagonist compounds, their synthesis and use ADORA2B, ADORA2A, ADORA3 ADORA1 4/4885ADORA2A 2/4885ADORA3 3/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback